Skip to content

Study · Case report or series · n = 1 · 2025

4 results

[Difelikefalin for severe chronic kidney disease-associated pruritus in a patient in dialysis].

Larsen GØ, Kjærgaard KD, Peters CD

Ugeskrift for laeger27 Jan 2025

PMID39936286 (opens in a new tab)DOI10.61409/v09240621 (opens in a new tab)PepBankPUB-39936286
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a haemodialysis patient with severe pruritus, difelikefalin reduced worst itch scores from 7-8 to 0.

    In plain wordsIn a haemodialysis patient, worst itch scores decreased after difelikefalin.

    Peptide
    Difelikefalin
    Outcome
    DecreaseWorst itch score
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    50 μg × 3/week · three weeksAs given in this study (human).

    Measurements

    Worst itch score
    0 points
    after treatment
    Worst itch score
    7 to 8 points
    before treatment

    Source sentences

    Summary
    The worst itch numeric rate scale (range: 0-10) dropped to 0 from 7-8 prior to DFK.
    2 context sentences
    Summary · context
    After three weeks, CKD-aP had improved markedly.
    Summary · context
    In this case report, a 72-year-old male haemodialysis patient with severe chronic kidney disease-associated pruritus (CKD-aP) was given difelikefalin (DFK) 50 μg × 3/week after unsuccessful standard therapy including fatty cream, steroids, antihistamines, gabapentinoids, and UV-light.
  2. 02HumanCase report or seriesSafety outcome

    In a haemodialysis patient, difelikefalin caused drowsiness that disappeared during treatment interruption.

    In plain wordsIn a haemodialysis patient, difelikefalin caused drowsiness that disappeared when treatment stopped temporarily.

    Peptide
    Difelikefalin
    Outcome
    Not applicableDrowsiness and resolution during interruption
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    50 μg × 3/weekAs given in this study (human).

    Source sentences

    Summary
    DFK caused drowsiness which disappeared when the treatment was paused.
    1 context sentence
    Summary · context
    In this case report, a 72-year-old male haemodialysis patient with severe chronic kidney disease-associated pruritus (CKD-aP) was given difelikefalin (DFK) 50 μg × 3/week after unsuccessful standard therapy including fatty cream, steroids, antihistamines, gabapentinoids, and UV-light.
  3. 03HumanCase report or seriesSafety outcome

    In a haemodialysis patient, difelikefalin was well tolerated after dose reduction to 25 μg × 3/week.

    In plain wordsIn a haemodialysis patient, the reduced difelikefalin dose was well tolerated.

    Peptide
    Difelikefalin
    Outcome
    Not applicableReduced-dose tolerability
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    25 μg × 3/weekAs given in this study (human).

    Source sentences

    Summary
    DFK dose was then reduced to 25 μg × 3/week which was well tolerated.
    1 context sentence
    Summary · context
    In this case report, a 72-year-old male haemodialysis patient with severe chronic kidney disease-associated pruritus (CKD-aP) was given difelikefalin (DFK) 50 μg × 3/week after unsuccessful standard therapy including fatty cream, steroids, antihistamines, gabapentinoids, and UV-light.
  4. 04HumanCase report or seriesEfficacy outcome

    In a haemodialysis patient treated with difelikefalin, the skin healed except for scratching scars.

    In plain wordsIn a haemodialysis patient treated with difelikefalin, the skin healed except for scratching scars.

    Peptide
    Difelikefalin
    Outcome
    IncreaseSkin healing
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The skin healed, except for scars caused by scratching.
    1 context sentence
    Summary · context
    In this case report, a 72-year-old male haemodialysis patient with severe chronic kidney disease-associated pruritus (CKD-aP) was given difelikefalin (DFK) 50 μg × 3/week after unsuccessful standard therapy including fatty cream, steroids, antihistamines, gabapentinoids, and UV-light.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.